RECITALSMaster Development and License Agreement • January 19th, 1999 • Verisign Inc/Ca • Services-computer programming services
MASTER DEVELOPMENT AND LICENSE AGREEMENTMaster Development and License Agreement • May 11th, 2010 • Neomagic Corp • Semiconductors & related devices
THIS MASTER DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into and effective as of May 5, 2010 (the “Effective Date”), by and between NeoMagic Corporation, a Delaware corporation, (“NeoMagic”) and Synapse Design Automation, Inc., a Delaware corporation (“Synapse”).
MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR PRODUCT BETWEEN ELITE PHARMACEUTICALS, INC. AND {***}Master Development and License Agreement • June 29th, 2012 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), dated March 16, 2012 (the “Effective Date”) between {***} ({***}) and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), organized under the laws of the State of Nevada, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”); {***} and Elite may sometimes hereinafter be referred to as a “Party” or collectively as the “Parties”.
Master Development and License AgreementMaster Development and License Agreement • July 1st, 2021
SECOND AMENDMENT TO THE MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGEN PHARMA, LLCMaster Development and License Agreement • August 9th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of July 24, 2017 (the “Amendment”), by and between SunGen Pharma, LLC, a limited liability company with its offices at 303C College Road East, Princeton, NJ 08540 (“SunGen”), and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), a corporation organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”), relating to that Master Development and License Agreement For Products dated August 24, 2016 and the First Amendment to the Master Development and License Agreement for Products both Between Elite Pharmaceuticals, Inc. and SunGen (together the “Agreement”);
AMENDMENT TO THE MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR {***} BETWEEN ELITE PHARMACEUTICALS, INC. AND MIKAH PHARMA, LLCMaster Development and License Agreement • November 14th, 2011 • Elite Pharmaceuticals Inc /De/ • Pharmaceutical preparations
This Amendment, dated as of November 1, 2011 (the “Amendment”), by and between Elite Pharmaceuticals, Inc. and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), both corporations organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”), and Mikah Pharma, LLC, a Delaware limited liability company with its offices at 20 Kilmer Drive, Hillsborough, New Jersey 08844 (“Mikah”) relating to that Master Development and License Agreement For {***} (the “Agreement”), dated August 27, 2010, by and between Elite and Mikah;
Certain information in this document has been excluded pursuant to Item (601)(b)(10) of Regulation S-K because it is not material and would likely cause competitive harm to the registrant if publicly disclosed. MASTER DEVELOPMENT AND LICENSE AGREEMENTMaster Development and License Agreement • March 12th, 2021 • Transact Technologies Inc • Computer peripheral equipment, nec • New York
This Master Development and License Agreement (this “Agreement”), dated as of July 20th, 2018 (the “Effective Date”) by and between TransAct Technologies Incorporated, having an address at One Hamden Center, 2319 Whitney Avenue, Suite 3B, Hamden, CT 06518, USA (“TransAct”) and [***] (“Developer”), each a “Party” and collectively the “Parties.”
MASTER DEVELOPMENT AND LICENSE AGREEMENTMaster Development and License Agreement • January 24th, 2019
MASTER DEVELOPMENT AND LICENSE AGREEMENT BETWEEN CONCERT PHARMACEUTICALS, INC., CELGENE INTERNATIONAL SÀRL, AND CELGENE CORPORATION FOR DEUTERATED PRODUCTS DATED AS OF APRIL 4, 2013Master Development and License Agreement • February 3rd, 2014 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Master Development and License Agreement (“Agreement”) dated as of this 4th day of April, 2013 (“Effective Date”), is between Concert Pharmaceuticals, Inc., a Delaware corporation having offices located at 99 Hayden Avenue, Suite 500, Lexington, Massachusetts 02421, USA (“Concert”), Celgene International Sàrl, a Swiss corporation located at Route de Perreux 1, 2017 Boudry, Switzerland (“CIS”), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, USA (“Celgene USA”). Each of Concert, CIS, and Celgene USA may be referred to hereinafter individually as a “Party” and together as the “Parties.”
FIRST AMENDMENT TO THE MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGEN PHARMA, LLCMaster Development and License Agreement • August 9th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of December 1, 2016 (the “Amendment”), by and between SunGen Pharma, LLC, a limited liability company with its offices at 303C College Road East, Princeton, NJ 08540 (“SunGen”), and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), a corporation organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”), relating to that Master Development and License Agreement For Products Between Elite Pharmaceuticals, Inc. and SunGen dated August 24, 2016 (the “Agreement”);
